The efficacy and safety of montelukast sodium in the prevention of bronchopulmonary dysplasia
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, S.B. | - |
dc.contributor.author | Lee, J.H. | - |
dc.contributor.author | Lee, J. | - |
dc.contributor.author | Shin, S.H. | - |
dc.contributor.author | Eun, H.S. | - |
dc.contributor.author | Lee, S.M. | - |
dc.contributor.author | Sohn, J.A. | - |
dc.contributor.author | Kim, H.S. | - |
dc.contributor.author | Choi, B.M. | - |
dc.contributor.author | Park, M.S. | - |
dc.contributor.author | Park, K.I. | - |
dc.contributor.author | Namgung, R. | - |
dc.contributor.author | Park, M.S. | - |
dc.date.accessioned | 2021-09-04T23:57:55Z | - |
dc.date.available | 2021-09-04T23:57:55Z | - |
dc.date.created | 2021-06-17 | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 1738-1061 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/95930 | - |
dc.description.abstract | Purpose: The purpose of this study was to evaluate the efficacy and safety of Montelukast sodium in the prevention of bronchopulmonarydysplasia (BPD). Methods: The Interventional study was designed as a multicenter, prospective, and randomized trial, with open labeled and parallel-experimental groups, 66 infants were enrolled and allocated to either the case group (n=30) or the control group (n=36) based on gestational age (GA). Infants in the case group were given Montelukast sodium (Singulair) based on their body weight (BW). Zero week was defined as the start time of the study. Results: The incidence of moderate to severe BPD was not different between the groups (case group: 13 of 30[43.3%] vs. control group: 19 of 36 [52.8%], P=0.912). Additionally, secondary outcomes such as ventilation index, mean airway pressure and resort to systemic steroids were not significantly different. There were no serious adverse drug reactions in either group, and furthermore the rate of occurrence of mild drug related-events were not significantly different (case group: 10 of 42 [23.8%] vs. control group: 6 of 48 (15.8%), P=0.414). Conclusion: Montelukast was not effective in reducing moderate or severe BPD. There were no significant adverse drug events associated with Montelukast treatment. © 2015 by The Korean Pediatric Society. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | Korean Pediatric Society | - |
dc.subject | cytokine | - |
dc.subject | montelukast | - |
dc.subject | abdominal distension | - |
dc.subject | airway pressure | - |
dc.subject | anemia | - |
dc.subject | Article | - |
dc.subject | candidiasis | - |
dc.subject | controlled study | - |
dc.subject | drug clearance | - |
dc.subject | drug efficacy | - |
dc.subject | drug safety | - |
dc.subject | gastrointestinal disease | - |
dc.subject | human | - |
dc.subject | ileus | - |
dc.subject | infant | - |
dc.subject | intervention study | - |
dc.subject | lung dysplasia | - |
dc.subject | multicenter study | - |
dc.subject | necrotizing enterocolitis | - |
dc.subject | open study | - |
dc.subject | prospective study | - |
dc.subject | randomized controlled trial | - |
dc.subject | sepsis | - |
dc.subject | septic shock | - |
dc.subject | staphylococcal bacteremia | - |
dc.subject | thrombocytopenia | - |
dc.title | The efficacy and safety of montelukast sodium in the prevention of bronchopulmonary dysplasia | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Choi, B.M. | - |
dc.identifier.doi | 10.3345/kjp.2015.58.9.347 | - |
dc.identifier.scopusid | 2-s2.0-84941561331 | - |
dc.identifier.bibliographicCitation | Korean Journal of Pediatrics, v.58, no.9, pp.347 - 353 | - |
dc.relation.isPartOf | Korean Journal of Pediatrics | - |
dc.citation.title | Korean Journal of Pediatrics | - |
dc.citation.volume | 58 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 347 | - |
dc.citation.endPage | 353 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002029776 | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordPlus | randomized controlled trial | - |
dc.subject.keywordPlus | sepsis | - |
dc.subject.keywordPlus | septic shock | - |
dc.subject.keywordPlus | staphylococcal bacteremia | - |
dc.subject.keywordPlus | thrombocytopenia | - |
dc.subject.keywordPlus | cytokine | - |
dc.subject.keywordPlus | montelukast | - |
dc.subject.keywordPlus | abdominal distension | - |
dc.subject.keywordPlus | airway pressure | - |
dc.subject.keywordPlus | anemia | - |
dc.subject.keywordPlus | Article | - |
dc.subject.keywordPlus | candidiasis | - |
dc.subject.keywordPlus | controlled study | - |
dc.subject.keywordPlus | drug clearance | - |
dc.subject.keywordPlus | drug efficacy | - |
dc.subject.keywordPlus | drug safety | - |
dc.subject.keywordPlus | gastrointestinal disease | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | ileus | - |
dc.subject.keywordPlus | infant | - |
dc.subject.keywordPlus | intervention study | - |
dc.subject.keywordPlus | lung dysplasia | - |
dc.subject.keywordPlus | multicenter study | - |
dc.subject.keywordPlus | necrotizing enterocolitis | - |
dc.subject.keywordPlus | open study | - |
dc.subject.keywordPlus | prospective study | - |
dc.subject.keywordAuthor | Leukotriene antagonists | - |
dc.subject.keywordAuthor | Montelukast | - |
dc.subject.keywordAuthor | Pharmacokinetics | - |
dc.subject.keywordAuthor | Premature infant | - |
dc.subject.keywordAuthor | Broncopulmonary dysplasia | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.